rs1760670

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_005373.3(MPL):​c.981-41G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.351 in 1,605,630 control chromosomes in the GnomAD database, including 104,111 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.31 ( 7925 hom., cov: 31)
Exomes 𝑓: 0.36 ( 96186 hom. )

Consequence

MPL
NM_005373.3 intron

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:3

Conservation

PhyloP100: 0.575

Publications

21 publications found
Variant links:
Genes affected
MPL (HGNC:7217): (MPL proto-oncogene, thrombopoietin receptor) In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated. [provided by RefSeq, Jul 2008]
MPL Gene-Disease associations (from GenCC):
  • thrombocythemia 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics, ClinGen
  • congenital amegakaryocytic thrombocytopenia
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, Ambry Genetics
  • congenital amegakaryocytic thrombocytopenia 1
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • familial thrombocytosis
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • hereditary isolated aplastic anemia
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.83).
BP6
Variant 1-43346404-G-A is Benign according to our data. Variant chr1-43346404-G-A is described in ClinVar as Benign. ClinVar VariationId is 259760.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.369 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MPLNM_005373.3 linkc.981-41G>A intron_variant Intron 6 of 11 ENST00000372470.9 NP_005364.1 P40238-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MPLENST00000372470.9 linkc.981-41G>A intron_variant Intron 6 of 11 1 NM_005373.3 ENSP00000361548.3 P40238-1
MPLENST00000413998.7 linkc.960-41G>A intron_variant Intron 6 of 11 1 ENSP00000414004.3 Q5JUY5
MPLENST00000638732.1 linkn.981-41G>A intron_variant Intron 6 of 9 1

Frequencies

GnomAD3 genomes
AF:
0.312
AC:
47424
AN:
151876
Hom.:
7921
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.224
Gnomad AMI
AF:
0.387
Gnomad AMR
AF:
0.367
Gnomad ASJ
AF:
0.406
Gnomad EAS
AF:
0.0734
Gnomad SAS
AF:
0.138
Gnomad FIN
AF:
0.332
Gnomad MID
AF:
0.404
Gnomad NFE
AF:
0.373
Gnomad OTH
AF:
0.367
GnomAD2 exomes
AF:
0.303
AC:
74837
AN:
246656
AF XY:
0.301
show subpopulations
Gnomad AFR exome
AF:
0.220
Gnomad AMR exome
AF:
0.303
Gnomad ASJ exome
AF:
0.415
Gnomad EAS exome
AF:
0.0676
Gnomad FIN exome
AF:
0.333
Gnomad NFE exome
AF:
0.379
Gnomad OTH exome
AF:
0.345
GnomAD4 exome
AF:
0.355
AC:
516068
AN:
1453636
Hom.:
96186
Cov.:
30
AF XY:
0.350
AC XY:
252955
AN XY:
723352
show subpopulations
African (AFR)
AF:
0.229
AC:
7639
AN:
33330
American (AMR)
AF:
0.314
AC:
13921
AN:
44302
Ashkenazi Jewish (ASJ)
AF:
0.411
AC:
10704
AN:
26050
East Asian (EAS)
AF:
0.0977
AC:
3875
AN:
39658
South Asian (SAS)
AF:
0.149
AC:
12799
AN:
85776
European-Finnish (FIN)
AF:
0.324
AC:
17263
AN:
53248
Middle Eastern (MID)
AF:
0.386
AC:
2143
AN:
5556
European-Non Finnish (NFE)
AF:
0.386
AC:
427274
AN:
1105618
Other (OTH)
AF:
0.340
AC:
20450
AN:
60098
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
17285
34570
51854
69139
86424
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
13158
26316
39474
52632
65790
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.312
AC:
47458
AN:
151994
Hom.:
7925
Cov.:
31
AF XY:
0.308
AC XY:
22837
AN XY:
74256
show subpopulations
African (AFR)
AF:
0.224
AC:
9305
AN:
41450
American (AMR)
AF:
0.366
AC:
5599
AN:
15280
Ashkenazi Jewish (ASJ)
AF:
0.406
AC:
1410
AN:
3470
East Asian (EAS)
AF:
0.0734
AC:
379
AN:
5164
South Asian (SAS)
AF:
0.139
AC:
670
AN:
4818
European-Finnish (FIN)
AF:
0.332
AC:
3495
AN:
10542
Middle Eastern (MID)
AF:
0.411
AC:
120
AN:
292
European-Non Finnish (NFE)
AF:
0.373
AC:
25358
AN:
67960
Other (OTH)
AF:
0.365
AC:
769
AN:
2106
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1601
3202
4803
6404
8005
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
468
936
1404
1872
2340
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.362
Hom.:
13642
Bravo
AF:
0.313
Asia WGS
AF:
0.131
AC:
456
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:2
Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

not specified Benign:1
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.83
CADD
Benign
9.8
DANN
Benign
0.68
PhyloP100
0.57
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1760670; hg19: chr1-43812075; COSMIC: COSV65245058; COSMIC: COSV65245058; API